dimanche 15 novembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· April 26, 2026

Has The Recent Rally Left Dell Technologies (DELL) Fully Priced Or Still Attractive?

View original at finance.yahoo.com
“For Dell Technologies, the model uses last twelve months Free Cash Flow of about $8.1b”
Verbatim excerpt from the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Sentiment shifts driven by headlines around key technology trends and investor interest in large established tech names can push prices away from what underlying cash flows and fundamentals suggest

    60% confidence
  • Dell Technologies shares trade at an 18.3% discount to intrinsic value, indicating the stock appears undervalued on a DCF basis

    60% confidence
  • Dell Technologies DCF intrinsic value is approximately $264.59 per share based on the 2 Stage Free Cash Flow to Equity model using TTM FCF of $8.1 billion

    60% confidence
  • Dell Technologies projected Free Cash Flow is $11.7 billion in 2031 based on analyst inputs and Simply Wall St extrapolation

    60% confidence
  • Dell Technologies has a valuation score of 3 out of 6, based on how often it screens as undervalued across several checks

    60% confidence

Data points we hold from this source

Dell Technologies · cash8.1 USD
Dell Technologies · margin-18.3 percent
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Sources réconciliées : aucun conflit ouvert pour l'instant.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,995
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,995 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
Has The Recent Rally Left Dell Technologies (DELL) Fully Priced Or Still Attractive?: Source | Via News | fr.via.news